USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics
This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.
Executive Summary—Key Findings
Executive Summary—Key Findings (continued)
Key Trends
Companies to Watch
Methodology and Scope
Market Overview—Introduction
Market Overview—Epidemiology
Market Overview—Epidemiology (continued)
Market Overview—Epidemiology (continued)
Physicians Treatment Guidelines
Physicians Treatment Guidelines (continued)
Physicians Treatment Guidelines (continued)
Physicians Treatment Guidelines (continued)
Market Size
Market Size—Segmentation
Market Forecast
Market Segmentation
Competitive Landscape Overview
Competitive Landscape—Marketed and Pipeline Products
Marketed Products—Anti-platelet Therapy
Pipeline Products—Anti-platelet Therapy
Marketed Products—Anti-thrombin Therapy
Marketed Products—Anti-thrombin Therapy (continued)
Pipeline Products—Anti-thrombin Therapy
Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs
Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs (continued)
Pipeline Products—Anti-hypertensives & Cholesterol Lowering Drugs
Pipeline Products—Others
Product Launch Timeline
Patent Expirations
ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials
ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)
Summary of Key Products to Watch
Product Dashboard: Plavix (clopidogrel)—Bristol-Myers Squibb
Product Dashboard: Brilinta (ticagrelor)—The Medicines Company
Product Dashboard: Angiomax—The Medicines Company
Product Dashboard: Zocor (simvastatin)—Merck
Product Dashboard: Xarelto (rivaroxaban)—Bayer
Product Dashboard: Alirocumab (RGN727)—Sanofi & Regeneron
Product Dashboard: Evolocumab (Repatha)—Amgen
Product Dashboard: Evacetrapib—Eli Lilly & Company
Product Dashboard: Losmapimod—GSK
Conclusions
Legal Disclaimer
Decision Support Database
Decision Support Database (continued)
Decision Support Database (continued)
Decision Support Database (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related industry research
16 Sep 2026 | North America | Customer Research
US Automotive Technicians’ Choice Survey, 2025
The 2025 US Automotive Technicians’ Choice study is an insightful voice-of-customer survey that highlights the tool preferences of automotive aftermarket service technicians. The survey of 400 automotive technicians across the United States used a combination of computer-assisted telephone and compu...
16 Sep 2026 | Global | Market Research
Apple Performance Tracker, Q1 2026
This Frost & Sullivan tracker provides metrics on Apple's quarterly performance (for both unit sales and revenues) for iPads, iPhones, Macs, and other products, such as iPods, Apple TVs, Beats Electronics, and Apple-branded and third-party accessories. It includes historical quarterly data for all t...
15 Sep 2026 | Global | Technology Research
Growth Opportunities in Workload Identity and Access Management, Non-Human Identity Security, Threat Exposure Management, and Blockchain Security
This edition of the Cyber Security Technology Opportunity Engine (TOE) showcases emerging cybersecurity innovators advancing AI-powered security, identity and access management, data security, threat exposure management, blockchain security, cyber incident response, network protection, and agentic A...
15 Sep 2026 | South Asia, Middle East & North Africa | Market Research
Future of Growth and Emerging Opportunities in the Gulf Cooperation Council, 2025–2030
The GCC has entered a period of strategic economic transformation as governments accelerate diversification efforts, strengthen economic resilience, and reduce dependence on hydrocarbon revenue amid heightened geopolitical uncertainty and evolving global trade dynamics. While the implications of the...
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Sriram Radhakrishnan |
| WIP Number | MB06-01-00-00-00 |
| Is Prebook | No |
A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %